Category Archives: Cell Therapy

DUBLIN--(BUSINESS WIRE)--The "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and Gene Therapy Market Report

The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 2021-2026.

The global cell and gene therapy market is observing significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually.

Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. In addition, the Europe market is witnessing steady growth due to the increased availability of funds from several public and private institutes.

There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products at a fast rate. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.

Europe Cell and Gene Therapy Market Segmentation

The Europe cell and gene therapy market research report includes a detailed segmentation by product, end-user, application, geography. A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling the growth of gene therapies. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields.

The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.

Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies.

While cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe.

Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.

Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing the patient's quality of life. Cell and gene therapies for certain types of cancers have been promising results.

The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer.

Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.

KEY QUESTIONS ANSWERED

1. What is the Europe cell and gene therapy market size and growth rate during the forecast period?

2. What are the factors driving the demand for CAR-T therapy in the European region?

3. How are strategic acquisitions aiding in market growth of cell and gene therapy products?

4. Which segments are expected to generate the highest revenues during the forecast period?

5. Who are the leading vendors in the European cell and gene therapy market?

INSIGHTS BY VENDORS

Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players on account of the presence of a large pool of target patient population with chronic diseases such as cancer, wound disorders, diabetic foot ulcer, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors.

While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors are preferring third-party service providers, including CMOs.

Prominent Vendors

Other Prominent Vendors

Emerging Investigational Vendors In Europe

For more information about this report visit https://www.researchandmarkets.com/r/6gqw7e

More:
Europe Cell and Gene Therapy Market Industry Outlook and Forecast Report 2021-2026 with Data-driven Insights on the Impact of COVID-19 -...

Global CAR-T cell therapy marketis set to witness a healthy CAGR of 46.35% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cases of cancer and rising demand for effective method to cure cancer are factor for the growth of this market.

CAR-T Cell Therapy market report is perfect for precision and accuracy that will help to meet business requirements at affordable rates. Such qualitative market research report helps businesses make out opinions and motivations perfectly and plan their schedule. With the help of this report, strengths and weaknesses as well as threats and opportunities for the business can be known. Defining the problem and objectives, collecting and generating market data with the supporting statistics, everything is performed in a streamlined process which makes this report very accurate. A team of highly encouraged and talented market analysts work constantly to form the best CAR-T Cell Therapy marketing report.

Get Sample Copy Of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-car-t-cell-therapy-market&kb

Few of the major competitors currently working in the global CAR-T cell therapy market are Autolus., Bellicum Pharmaceuticals, Inc., Bluebird Inc., CELGENE CORPORATION, Cellectis, Celyad, Eureka Therapeutics, Fortress Biotech., Immune Therapeutics, Juno Therapeutics, Kite Pharma, Novartis AG, Sorrento Therapeutics, Inc., TILT Biotherapeutics, Ziopharm Oncology, Inc., TrakCel, Tmunity Therapeutics, Promab Biotechnologies, Poseida Therapeutics, Inc., Minerva Biotechnologies Corporation and others.

Market Drivers

Market Restraints

Key Developments in the Market:

And More..Get Detailed TOC Athttps://www.databridgemarketresearch.com/toc/?dbmr=global-car-t-cell-therapy-market&kb

Segmentation:Global CAR-T Cell Therapy Market

By Target Antigen

By Application

ByGeography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-car-t-cell-therapy-market&kb

Reasons to buy this report:

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Global CAR-T Cell Therapy Market Witnessing Enormous Growth ||CELGENE CORPORATION, Cellectis, Celyad, Eureka Therapeutics, Fortress Biotech KSU | The...

London, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition)-Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, NHL, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma and Others), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100 and others), Key Players and Key Regions (North America, Europe, Asia Pacific, Latin America, MENA, and Rest of the World): Industry Trends and Global Forecasts, 2020-2030 report to its list of offerings.

Having demonstrated the ability to selectively eradicate tumor cells from the body with minimal treatment-related side effects, T-cell therapies have emerged as a promising therapeutic strategy for advanced stage cancers. With three approved therapies, namely KYMRIAH (Novartis), YESCARTA (Gilead Sciences) and TECARTUS (Gilead Sciences), the T-cell immunotherapy pipeline has evolved significantly over the past few years, with several mid to late-stage (phase II and above) candidates anticipated to enter the market over the next 5-10 years.

To order this 990+ page report, which features 255+ figures and 405+ tables, please visit this link: https://www.rootsanalysis.com/reports/view_document/t-cell-therapies-market/261.html

Key Market Insights

Over 975 T-cell candidate therapies are currently approved / under development CAR-T cell products continue to dominate the clinical / preclinical pipeline, representing 78% of the total number of molecules, followed by TCR (15%) and TIL (7%) based therapies. Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 10% are being evaluated in late clinical stages (phase II and above). Examples of late-stage clinical candidates include bb2121, JCAR017, GSK3377794, IMCgp100 and lifileucel.

Currently, the focus is on therapies for treating hematological malignanciesMore than 95% of the products in the development pipeline are presently being developed to treat various types of cancers, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma and melanoma. Only 2% of pipeline candidates are being evaluated for the treatment of non-oncological indications.

Extensive efforts are underway to improve the CAR constructsMajority of the CAR-T cell therapies in the clinical development, including the three recently approved products, are based on second generation CARs. Further, lentivirus and retrovirus are presently the preferred type of vectors used for transduction of CAR constructs into T-cells.

China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitalsIn the last 10 years, over 410 clinical trials, evaluating various types of CAR-T cell therapies, were registered across different geographies; interestingly, over 50% of thesetrials are being conducted in China.

Partnership activity within this domain has grown at a CAGR of 42%, between 2005 and 2020 Since 2005, more than 340 agreements were inked related to T-cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (25%), technology licensing (18%) and product development and commercialization agreements (11%).

Over USD 17 billion has been invested by both private and public investors, across more than 270 instancesIt is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), initial public offerings (13%) and grants (13%).

North America and Europe are anticipated to capture over 83% of the market share by 2030With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 12.2% during the next decade. The market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visithttps://www.rootsanalysis.com/reports/261/request-sample.html

Key Questions Answered

The USD 23 billion (by 2030) financial opportunity within the T-cell immunotherapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:

The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/t-cell-therapies-market/261.html or email sales@rootsanalysis.comYou may also be interested in the following titles:

Read this article:
The T-cell immunotherapy market is projected to grow at an annualized rate of 12.2%, claims Roots Analysis - GlobeNewswire

Close to a year after Maryland-based CDMO Vigene Biosciences cut the ribbon on its headquarters, spiking demand for cell and gene therapy has prompted the company to lay out a major manufacturing upgrade in its home state.

Vigene is picking up a lease for 52,000-square-feet of manufacturing space in Montgomery County, Maryland, situated near its existing headquarters in Rockville. The expansion is set to bring the company's total lab and production space up to 110,000 square feet and, by 2025, will see up to 245 new hires join Vigene's current workforce of 125.

The new facility, located at 14200 Shady Grove Road, will complement existing R&D and manufacturing operations at Vigene's home base as the company faces growing demand for its cell and gene therapy products. Vigene's expansion has snared some financial perks from the state, too, including a $1,225,000 loan from the Maryland Department of Commerce, which is contingent on job creation and capital investment.

Innovation in Rare Disease: Making Progress with Cell & Gene Therapies A Webinar Series from the Rare Disease Innovations Institute and Syneos Health

Join patients and their families, legislators, industry experts, advocates and sponsors to discuss education initiatives, recent advancements and the future promise of cell and gene medicine, and current patient experiences with these therapies.

RELATED: Cognate beefs up cell, gene therapy manufacturing with new plants in U.S., EU

The company is keeping its own spending on the site under wraps, Jeffrey Hung, Ph.D., chief commercial officer of Vigene, said over email. "It suffices to say that we are going to invest heavily on the facility to qualify and commission it for commercial production purpose," he added.

With the new site, Vigene will add five more GMP suites to the 10 it operates now, Hung said. Specifically, the company plans to commission and set up two 2,000-liter single-use bioreactor suites, where upstream and downstream production trains will be located on the same floor for commercial viral vector production. Another floor will house multiple large-scale fermenters for commercial plasma production, he said.

Formed in 2012, Vigene specializes in gene therapies for patients with cancers and serious genetic disorders. It develops, manufactures and distributes adeno-associated viruses, lentiviruses, retroviruses, adenoviruses and plasmid viral vectors for gene delivery.

RELATED: Fujifilm continues CMDO expansion spree with $76M in funding for new Boston site

The company has checked into the COVID-19 fight, too, signing on to produce clinical materials for Maryland compatriot Altimmune's nasal vaccine candidate. Vigene in July agreed to churn out both drug substance and drug product for studies on the vaccine, which registered for a phase 1 trial in late December.

On Dec. 23, Altimmune revealed the FDA had slapped the investigational new drug application for its vaccine, AdCOVID, with a clinical hold, citing the need for protocol modifications and additional chemistry, manufacturing and control data. The company responded to the hold and, at the time, said it didn't expect the move to significantly disrupt its clinical timeline.

Altimmune has also added Swiss CDMO Lonza as a production partner on its nasal vaccine, and it previously set the goal to crank out at least 100 million AdCOVID doses in 2021.

Meanwhile, Vigene's expansion comes shortly after the christening of its Rockville HQ. It was just a year ago that we cut the ribbon at Vigenes new custom-built headquarters and already the growing demand for its gene and cellular therapy products requires additional physical expansion, Benjamin Wu, CEO and president of the company, said in a release.

Read the original here:
CDMO Vigene plots cell and gene therapy manufacturing expansion, adding 245 new jobs along the way - FiercePharma

The global stem cell therapy market is expected to witness a CAGR of 10.6% during the forecast period 2019-2024, and is also anticipated to reach USD 214.5 million by 2024. Growing awareness related to the therapeutic potency of stem cells, development of infrastructure related to stem cell banking and processing, development of advanced genome-based cell analysis techniques, and increasing private-public investment for the development of stem cell therapies are driving the growth of the stem cell therapy market.

Get a free copy of sample report: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/request-sample

Supportive regulations to drive the growth of the stem cell therapy market

Supporting regulations across developing countries, increasing prevalence of chronic diseases, technological advancement in healthcare, cellular therapies are the major advancements in transforming healthcare and identification of new stem cell lines are also fueling the growth of the stem cell therapy market.

Diseases such as osteoarthritis, multiple sclerosis, heart failure, hearing loss and cerebral palsy are some of the diseases that could be treated using stem cell therapies. For instance, according to the WHO by 2050, it is estimated 900 million people will have disabling hearing loss. Moreover, 60 percent of childhood hearing loss is due to preventable causes.

Allogenic stem cell therapy market to hold the larger share in the market

There are two types of stem cell therapy, allogeneic and autologous. Of both, allogenic segment account for the larger share and is also predicted to grow at the faster rate in the coming years in the market due to its extensive therapeutic applications, increasing commercialization of allogeneic products, easy production scale-up process, and growing number of clinical trials related to allogeneic therapies.

The stem cell therapy market has been segmented by therapeutic application into gastrointestinal diseases, musculoskeletal disorders, surgeries, cardiovascular diseases, and wound and injuries. Musculoskeletal disorders category contributed the largest revenue in the market due to increasing prevalence of musculoskeletal disorders and bone & joint diseases, increasing availability of stem cell-based products for the treatment of musculoskeletal disorders, and growing patient preference for effective & early treatment strategies.

Do you have any specific research requirement? Ask for customization: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/customize-report

The global stem cell therapy market has also been segmented by cell source into adipose tissue-derived mesenchymal stem cell, cord blood cells and bone marrow-derived mesenchymal stem cells. Of all the categories, the bone marrow-derived mesenchymal stem cells are increasingly being used for therapeutic applications.

North America offers huge opportunities for stem cell therapy industry players

The North American stem cell therapy market will remain the largest during the forecast period. The region is further predicted to observe the fastest growth during the forecast period in the global market owing to technological upgradation and large capital invested in the research and development activities. Moreover, increasing number of clinical trials to evaluate therapeutic potential of products, increasing prevalence of chronic diseases, the growing patient base for target diseases, growing public awareness related to the therapeutic potency of therapy, and increasing public-private funding & research grants for developing safe and effective stem cell therapy products are also supporting the growth of the North American stem cell therapy market.

Investing in research and development is the key strategy adopted by the market players

Major players in the industry are investing in the development of innovative and new products, which is strengthening their position in the stem cell therapy market. In February 2018, MEDIPOST announced that FDA has approved its stem cell-based Alzheimers disease drug, NEUROSTEM for clinical trials. Similarly, in March 2017, Osiris Therapeutics launched Prestige Lyotechnology, a method for storage of living cells and tissues.

Some of the key players operating in the stem cell therapy industry are Osiris Therapeutics, Inc., RTI Surgical, Inc., MEDIPOST Co., Ltd., Nuvasive, Inc., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., and Allosource.

More from VynZ Research

Global Stem Cell Banking Market Analysis and Forecast to 2024

The global stem cell banking market is growing at a CAGR of 9.1% during the forecast period reaching USD 10.5 billion by 2024, due to the development of novel technologies of storage, preservation and processing. Stem cell banking is the method of accumulating cord blood, extorting and cryogenically freezing its stem cells for forthcoming use. Cord blood stem cells are used for treating blood diseases such as sickle cell disease, leukemia, and thalassemia. The global stem cell banking market is growing at a significant rate due to the development of novel technologies of storage, preservation and processing. The market has witnessed a high demand for placenta stem cells over the last few years, due to the increasing public awareness regarding the therapeutic prospective of stem cells.

Explore more at: https://www.vynzresearch.com/healthcare/stem-cell-banking-market/request-sample

Global Protein Expression Market Analysis and Forecast to 2024

The global protein expression market was evaluated at USD 1,873.1 million in 2018. The protocol for expression of proteins makes use of expression vectors, competent cells, reagents, instrument, and services. The reagents are the estimated to hold the largest share due to large volume used in the bio-experiments. The significant growth in the protein expression industry is primarily due to the increasing funds from government and non-government organization for protein research, the soaring prevalence of chronic diseases, rising life science industry.

Explore more at: https://www.vynzresearch.com/healthcare/protein-expression-market/request-sample

U.S. Protein Expression Market Analysis and Forecast to 2024

The U.S. protein expression market is expected to grow at a CAGR of 11.6% during the forecast period with its market size predicted to reach USD 1.2 billion by 2024. The U.S. protein expression market is primarily driven by the factors such as the increasing prevalence of chronic diseases, increasing investment for recombinant protein expression, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country. Prokaryotic expression systems and mammalian cell expression systems are the major contributors to the protein expression industry in the region.

Explore more at: https://www.vynzresearch.com/healthcare/us-protein-expression-market/request-sample

Contact Us:

VynZ Research

Call: +91-996-028-8381

Toll Free (U.S. and Canada): +1-888-253-3960

Email: enquiry@vynzresearch.com

Connect with Us: LinkedIn | Facebook | Twitter

Read the original:
Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier

Pan Cancer T B.V., a biotech spin-off from the Erasmus Medical Center founded by Prof. Dr. Reno Debets (CSO) and Dr. Dora Hammerl (VP R&D), announces the closing of a seed investment and start of operations. Together with Katrien Reynders-Frederix (CEO), the team is committed to the discovery and development of novel TCR therapies against solid tumors such as triple negative breast cancer, bladder cancer, lung cancer, and glioma. Seed investors are Swanbridge Capital and Van Herk Ventures, and the Company is further awarded a Health~Holland grant for a publicprivate-partnership with Erasmus Medical Center.

Over the past decades, innovations in cancer treatments have improved the survival of cancer patients. Despite successes of therapieslike Chimeric Antigen Receptor (CAR) T-cell therapies, the vast majority of solid cancers remain refractory to such treatments. Pan Cancer T introduces new treatment options for hard-to-treat solid cancers through adoptive therapy with T-cells that are genetically engineered with TCRs. TCR therapy exploits the ability of the immune cells, in this case T-cells, to specifically and efficiently recognize and kill malignant cells according to the expression of iintracellular target antigens. The Company develops safe and first-in-class TCR T-cell therapies against unique and proprietary targets that are exclusively expressed by multiple tumor types but are absent in healthy tissues. In addition, the Company delivers smart treatments that act against tumor micro-environmental hurdles and maximizes the efficacy of TCR T-cells towards solidtumors.

Katrien Reynders-Frederix, CEO of Pan Cancer T, said: "Immunotherapy currently holds a large potential for cancer treatment. Adoptive T-cell therapy is one of the most promising approaches that has already proven its feasibility and clinical benefit in tumors in several clinical trials. The team is committed to develop safe and potent therapies, and the first data underscore the potential of our lead program where T-cells are directed against the PCT-1 target. Thanks to the support of our investors and Health~Holland, we are able to advance our pre-clinical programs. I am honored to be part of a company that has the potential to positively impact millions of lives. We are looking forward to further expanding our investor base and raising a Series A financing round to accelerate our programs.

Reno Debets, CSO of Pan Cancer T, Professor at Erasmus Medical Center and specialist in T-cell immunity and adoptive therapy of tumors, stated: The fact that tumors grow and metastasize is often a consequence of immune evasion, pointing to the inherent ability of T-cells to selectively recognize and potently destruct tumors. To translate this ability towards patient care, we exploit fundamental platforms established over the last decade in our laboratory. Our platforms cover tumor-selective targets for T-cells, technologies to identify safe and effective TCRs as well as strategies to overcome Tcell suppressive effects of the tumor micro-environment. It is exactly this research fundament that goeshead-on against the current challenges of immunotherapies. I am really proud and confident that with our enthusiastic team we will make important steps towards improved patient care.

Thijs Spigt, Director of Technology Transfer Office at Erasmus Medical Center Rotterdam: Erasmus MCs mission is to provide excellence in patient care, education and research. A key strategic element supporting this mission is the valorization of research findings. The establishment of Pan Cancer T, together with Swanbridge and Van Herk, fits a series of perfect examples how Erasmus MC is able to translate excellent research into development of new therapies for difficult to treat cancer types. We continue to support the team and look forward to a prosperous future for the company.

Cillian King, Investment Manager at Swanbrigde Capital, commented: Recent advances in our understanding of the immune system and its role in cancer have resulted in the uptake of many new immunotherapies into clinical practice. However, despite remarkable results for some patients, many patients still lack effective treatment options, particularly those with solid tumors with immune suppressive microenvironments. We believe the science, expertise, and vision behind Pan Cancer T has the potential to profoundly impact patient outcomes and we look forward to supporting the company along this exciting journey.

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

See the rest here:
TCR T-cell therapies for hard-to-treat solid tumors - SelectScience

Stem Cell Therapy Market

Stem Cell Therapy Market Projections (2020-2029): The Global market Stem Cell Therapy theologizes is the most recent of the world business market curves. The report prospects the current and frequent collectors, technological innovations, product supplementation, and their representation of performance broadly across the foreign market.

Thisphenomenalstudy on world-widebusiness includes the results of vital primary and secondary resources. These research findings are accepted by the companys skilled analysts and experts, providing rich in-depth information to associated partners, appraisers as well as captains of the industry.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/148234

Prominent players in the industry covered in the report:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Market split by Type, can be divided into:AutologousAllogeneic

Market split by Application, can be divided into:Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

Market split by Sales Channel, can be divided into:Direct ChannelDistribution Channel

Ourstudypasses through ahaven ofprofound qualitative and quantitativeresearch by industryexperts andprofessionals.Within the reportcontributes a broadperceptionof thepast as well ascurrent marketvista,which implies future statistics and prospects in position with the technical developments over time. Furthermore, the report includes and provides analyses of demand and supply, microeconomic and macroeconomic elements, administrative components and growth indices through the Stem Cell Therapy marketplace. The report outlines keytacticsutilized bykey market participants.

Reach us to quote the effective price of this report (UPTO 50% OFF) @ https://www.regalintelligence.com/check-discount/148234

This report provides an accurate understanding and discovery of key geographic areas underway with market Stem Cell Therapy, including critical segments and additional segments.The report sets out aspects of territorial growth and the size and scope of the market. Additionally, the report also deals with trading information such as business range, cost and revenue margin as well as gross value. However, this understanding assists readers in the conduct of consumer experts as well as major tactic to reach market share.

Substantivebeneficiaries:

Additional Information:

This reportcontributes to the following:

Important questions answered within this report:

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us:Regal Intelligence: http://www.regalintelligence.comPh no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Go here to read the rest:
Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi...

(Feb 2021) The latest report published by Polaris Market Research, titled Global Car T Cell Therapy Market by Company, Region, Type and Application, Forecast for 2026provides key information about the current status and prospects of the market. The report focuses on market size, share, growth, emerging trends and market area analysis. The research also includes a comprehensive analysis of various market factors, including market drivers, restrictions, trends, risks, and opportunities that are common in the market.

The report provides an in-depth analysis of the global Car T Cell Therapy market, which can help market participants design strategies and improve the profitability of their businesses. The study also outlines the major companies that exist in the market and their market shares, growth rates and product launches. The report covers the rapidly changing market scenario and covers the initial and future assessment of the impact

Ask for Sample copy: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

The report produced by Polaris Market Research is widely known for its accuracy, because it is composed of precise charts, tables and graphs that clearly depict the development of past products and their market performance and predict future trends. It uses statistical surveys for SWOT analysis, PESTLE analysis, predictive analysis and real-time analysis.

Manufacturers covered in this report are:

Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US),

*Note: Additional companies can be included on request

The study is a source of reliable data on:

Research methodology

In order to infer the market size, the report considered various aspects on the basis of secondary research. In addition, data points such as product segmentation and market segmentation are also divided by end use. It also combines the qualitative opinions of the main interviewees to arrive at an appropriate market estimate. The forecast provided in the report assesses the total revenue generated by the Car T Cell Therapy market and the expected revenue contribution.

When formulating market forecasts, the report will determine the size of the current market, which is the basis for predicting how the market will form in the near future. Market Insights triangulates data through different analysis based on supply side, demand side and other dynamics. The report not only provides CAGR forecasts, but also analyzes the market based on key parameters such as year-on-year (Y-o-Y) growth to understand the predictability of the market and identify the right opportunities.

To get Incredible Discounts on this Report, Click Here @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-discount-pricing

The regional analysis covers:

Car T Cell Therapy Market Segmentation:

CAR-T Cell Therapy Market Size and Forecast 2017 2026 by Target Antigen

CAR-T Cell Therapy Market Size and Forecast by Indication

Highlights of the report:

Benefits of buying reports:

If you have any specific requirements, kindly let us know and we will help customizing the same. Speak to our analysts to know more @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/speak-to-analyst

THANKS FOR SPENDING YOUR VALUABLE TIME ON THIS VALUABLE PIECE OF INFORMATION !

About Polaris market Research

Polaris market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across industry verticals.

Contact Us

Corporate Sales, USA

Polaris market Research

Phone: 1-646-568-9980

Email:sales@polarismarketresearch.com

Web:www.polarismarketresearch.com

Follow this link:
Car T Cell Therapy Market is projected to grow at a healthy CAGR over the next years by regions | Keyplayers :Bluebird Bio (US), Celgene Corporation...

Undaunted by the challenges the COVID-19 pandemic unleashed on the world the expected surge of cell and gene therapies already in the pipeline and on the horizon will continue to materialize, and with them the complexity of riding that wave of innovation.

Just two years ago the U.S. Food and Drug Administration (FDA) forecast that it would be flooded by 2020 with about 200 Investigational New Drugs a year on top of the more than 800 active cell-based or gene therapies it was already processing. The agency projected that by 2025 it would be approving anywhere between 10 to 20 new cell and gene therapy products a year. By 2024, the FDA and the pharmaceutical and biopharmaceutical industries expect more than 40 new and innovative cell and gene therapies will be available on the market.

Although the pandemic disrupted drug discovery and development efforts early in the crisis, the industry has been quick to respond and adjust. The CG&T market will likely slow from $6.68 billion in 2019 to $6.92 in 2020 because of the pandemic, yet it is forecast to recover and grow to an estimated $13.23 billion by 2023, according to Researchandmarkets.com.

There is more momentum than ever before to bring these innovative medicines to market, said Doug Cook, president of Commercialization Services and Animal Health at AmerisourceBergen. The influx of therapies offers tremendous promise and hope to patients with conditions where there are few treatment options and no cures. But these complex products introduce new considerations throughout the commercialization journey, so its critical that manufacturers work with a partner that can help them navigate challenges at each stepfrom pre-clinical and commercial logistics to market access strategies and patient support solutions.

Because CG&T are derived from a patients own cells, time and temperature have become critical factors from the moment they are extracted on through the manufacturing process and then returned as a curative life-saving therapy. As such, there is little room for failure or delay throughout the supply chain.

Given the narrow window of viability of these therapies they need to be shipped as quickly as possible to preserve the time the cells are active. With such a constraint on the time those cells are viable, the pressure on logistics providers has become even more acute. Clearly, supply chain companies that have larger networks and better access to more depots are more advantageous for manufacturers, but more importantly, for patients.

The complexity of these treatments can be staggering both from a development perspective and on into storage and transportation, Cook said. For the first time, the patient is now part of the supply chain where they used to be at the end of it, and thats really different than anything weve seen before.

Many, if not most, of CG&T require ultra-frozen storage from the development stage on through to the application to the patient. This is an element of the supply chain the public is becoming acutely aware of as a result of the COVID-19 pandemic. For example: Pfizer-BioNTechs COVID-19 vaccine must be stored in containers that can achieve between -80 to -60 degrees Celsius. C> require storage conditions from ultracold (-80 degrees Celsius) down to cryogenic temperatures (-135 to -150 degrees Celsius). To ensure the product remains viable throughout transport, the shipping containers must have the ability to keep a constant monitor of the temperatures as well as have real-time GPS tracking.

The shorter the shelf life of the cell therapy, the more intense the logistical challenges. To achieve successful outcomes in what are very patient-centric treatmentsoften referred to as a vein-to-vein supply chainrequires manufacturers to partner with experienced and technologically advanced wholesalers and distributors that have a global reach and ability to address issues with customs and country-specific regulatory requirements.

As the wave of these therapies begins to swell past the approval stage, the need for infrastructure that can handle CG&T has to be in place to avoid bottlenecks and delays that could limit patient access.

Because of all the complexity, handoffs are where mistakes happen, and you need a partner who focuses on all those small details and makes the process seamless, Cook said. This is where experience matters, and capabilities are essential.

In order to continue to meet and exceed its capabilities, early last year AmerisourceBergen strengthened its logistics offerings by integrating its global logistics provider, World Courier, with ICS, its third-party (3PL) provider. Now fully integrated, the service offers a complete cryogenic supply chain. World Courier and ICS offer vapor-charged cryogenic storage with fully automated technology and temperature-controlled transport from a manufacturers location to a storage facility and then to each point of care in dry shipment containers. The group has extensive experience in navigating international borders while maintaining temperature requirements.

With a global network of more than 140 offices, World Couriers has the ability to provide cryogenic shipping solutions that are close to patient and manufacturing locations, which provides much more flexibility as well as cutting response times for patient and hospital needs.

Its become clear as we navigated through COVID that everything has to be connected in ways they werent before, Cook said. As a result, weve invested in more technology services to better position ourselves to support CG&T and play the role of partner and connector more than ever before.

And we are always looking at ways to offer more cohesive capabilities.

To learn more about how AmerisourceBergen anticipates supply and demand and how we do business and the role of distributors in the supply chain check out:https://www.amerisourcebergen.com/pharmaceutical-distribution/value-of-the-distributor

Visit link:
Meeting the commercialization challenge of a surging gene and cell therapy market - FierceBiotech

Tricia Derges, a member of the Missouri House of Representatives and doctor, has been indicted by a grand jury for among other things allegedly injecting people with amniotic fluid and telling them mesenchymal stem cells made it a miracle cure. Derges has pled not guilty, and IFLScience cannot assess the accuracy of the charges. However, the case brings attention to growing use of unproven and dangerous stem cell treatments.

The case against Derges is being taken by Tim Garrison, the U.S. Attorney for Missouri's Western District. Garrison alleges Derges acquired stem cell-free amniotic fluid and told patients it contained stem cells that would cure a variety of conditions, charging them four times what the fluid cost her to inject them with it. Garrison charged Derges with false statements over the use of the fluid, as well as illegal distribution of controlled substances and wire fraud in relation to other activities at the clinics she runs.

Among long posts on her Facebook page professing her innocence, Derges posted a picture of David and Goliath, writing, I actually thought that I was making a difference. What I didnt account for was how much satan would fight back.

Whatever the truth of the allegations in Derges' specific case, by charging astate representative, Garrison has highlighted what is definitely a growing problem: deceptive use of stem cell therapies.

Multipotent stem cells have the remarkable capacity to convert into the cells that make up many bodily tissues. The hematopoietic stem cells have been used for decades to treat leukemia with well-proven results. Hundreds of other applications are either under investigation in the laboratory, or currently in clinical trials, but a much smaller number have been approved by America's FDA and equivalent bodies worldwide.

Understandably, many people don't feel able to wait, making them vulnerable to quack doctors for whom stem cells are the 21st Century snake oil. Unlike embryonic stem cells, which often originate from abortions, amniotic stem cells are seen as an alternative acceptable to pro-life individuals. However, having been discovered more recently, research into them is less advanced, making any therapeutic value speculative.

Dirges' vocal opposition to abortionpresumably made amniotic cells attractive to her for this reason, but Garrison alleges the fluid Derges was using didn't even contain stem cells. Moreover, he claims the University of Utah where Derges bought the fluid told her that, so she would have known it couldn't possibly have been effective.

Derges gained a medical degree from the Caribbean Medical University in Curaao and ran a series of low-cost medical clinics, where volunteers saw patients and recommended to her what medication to prescribe. Although licensed as an assistant physician, Derges was not accepted into a post-graduate residency program and was not licensed as a physician. She fought to change licensing rules, and ran for Missouri state District 140, narrowly winning the Republican primary before being unopposed last November. Since being elected, Derges has made changing the law on physician licensing her first priority.

In a statement, Garrison allegedDerges used the fluid on patients with everything from Lyme disease to erectile dysfunction and kidney disease, despite the improbability a single fluid would cure such different ills. Although Derges' clinics are famous for charging just $5 for an ordinary visit, the costs of this treatment averaged $40,000 per patient.

The program came to Garrison's attention after she appeared on television claiming the same amniotic fluid should be used to treat COVID-19 and making similar claims on Facebook.

H/T Springfield News Leader

Original post:
Missouri State Representative Indicted Over Alleged Stem Cell Therapy Scam - IFLScience